California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage 
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies 
GLP-1 Weight Loss Pills Set to Reshape Food and Fast-Food Industry in 2025 
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions 
Winter Storm Devin Triggers Massive Flight Cancellations and Travel Disruptions Across the U.S. 
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares 
Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy 
California DMV Proposes New Safety Rules for Autonomous Vehicles After Waymo Incidents 
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market 
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands 
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector 
Nvidia and Groq Strike Strategic AI Inference Licensing Deal 
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio 
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing 
BP Nears $10 Billion Castrol Stake Sale to Stonepeak 
Brazilian Oil Workers’ Strike Continues as Key Petrobras Union Rejects Proposal 
TUCSON, Ariz., Nov. 03, 2016 -- HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments and reagents for molecular profiling applications, today announced that the Company will release 2016 third quarter financial results after market close on Monday, November 14, 2016. Company management will host an investment-community conference call beginning at 4:30pm Eastern Time on Monday, November 14 to discuss these results and answer questions.
Individuals interested in listening to the conference call may do so by dialing (866) 394-4225 for domestic callers, or (678) 509-7535 for international callers (conference ID: 9555990), or from the webcast on the “Investors” section of the Company’s website at: http://www.htgmolecular.com. The webcast will be available on the Company’s website for 90 days following the completion of the call.
About HTG:
Headquartered in Tucson, Arizona, HTG’s mission is to empower precision medicine at the local level. In 2013 the company commercialized its HTG Edge instrument platform and a portfolio of RNA assays that leverage HTG's proprietary nuclease protection chemistry. HTG’s product offerings have since expanded to include its HTG EdgeSeq product line, which automates sample and targeted library preparation for next-generation sequencing. Additional information is available at www.htgmolecular.com.
Contact: Westwicke Partners Jamar Ismail Phone: 415-513-1282 Email: [email protected] TJ Johnson President / CEO HTG Molecular Diagnostics Phone: 520-547-2827 x130 Email: [email protected]
